Table Of Content
Clinical trial design is an important aspect of interventional trials that serves to optimize, ergonomise and economize the clinical trial conduct. The purpose of the clinical trial is assessment of efficacy, safety, or risk benefit ratio. A well-conducted study with a good design based on a robust hypothesis evolved from clinical practice goes a long way in facilitating the implementation of the best tenets of evidence-based practice. A robust well-powered trial adds to the meta-analyzable evidence base and contributes huge quanta to our knowledge of dermatological practice. This article sets out to describe the various trial designs and modifications and attempts to delineate the pros and cons of each design and attempts to provide illustrative samples for the same where possible. Blinding is a fundamental tool in clinical trial design and a powerful method for preventing and reducing bias.
Professional development
The Company also announced acceptance of its HB-200 study abstract as an oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in the head and neck cancer session to be held on June 4, 2024. The presentation will include data for approximately 40 head and neck cancer patients treated with HB-200 in combination with pembrolizumab. The Company anticipates the first patient will be enrolled in the fourth quarter of 2024. Further, it is important to specify parameters for all stopping rules for stopping the trial early. In a Frequentist design, stopping rules are defined in terms of boundaries for safety, efficacy and futility; see Chapter 8 in Ellenberg, Fleming, and DeMets (2002). In a Bayesian design, stopping rules are typically defined in terms of posterior probabilities or predictive probabilities; see Saville et al. (2014).
High risk, high benefit trial
This paradigm is useful only for studies with binary outcomes and are most useful when the anticipated effect size being evaluated is large. The play-the-winner and the drop-the-loser designs aim to favor the group with the best chance of success by increasing the probability of patients being randomized to that group. The probability of being randomized to one group or another is modified according to the results obtained with previous patients. The response of each patient after treatment plays an essential role in the determination of subsequent compositions of the study population.
Clinical Trials: Design, Strategy, and Analysis
In this way they aimed to help target patient subpopulations that might benefit from specific interventions, rather than group different PLP subsets to receive a therapy that might only works on a small number of them (44). Such a mechanism-based approach may help direct clinical trials toward positive outcomes. For this reason, the NIH proposed a mechanistic data model to design psychiatry trials – the RDoC (Research Domain Criteria) framework (45). Phase III trials provide additional information about effectiveness, efficacy and safety, giving a clearer picture of the intervention’s risk-benefit ratio with a potential to change clinical practice (21).
This is often easier than trying to make the two interventions look like each other. Participants are then randomized to receive one active treatment and one placebo (but are blinded). The downside of this approach is that the treatment schedules become more complicated (i.e., each participant must adhere to two regimens).
Build your subject-matter expertise
How a community-based approach can improve clinical trial diversity - EY
How a community-based approach can improve clinical trial diversity.
Posted: Tue, 16 Apr 2024 10:45:00 GMT [source]
Key features of clinical trials that are used to meet this objective are randomization (possibly with stratification), adherence to intent-to-treat (ITT) principles, blinding, prospective evaluation, and use of a control group. Compared to other types of study designs (e.g., case-control studies, cohort studies, case reports), randomized trials have high validity but are more difficult and expensive to conduct. Before any treatment is approved and offered to patients in the general population, rigorous evidence of its safety and efficacy must be shown. In this article, we present some general principles of good clinical trial design, which are often used as the basis to evaluate the quality of the evidence presented in manuscripts reporting trial results. By trial “design,” we include aspects from background knowledge and trial rationale to sample size and interim monitoring rules. Given that mistakes in design can seldom be later rectified, we strongly encourage investigators to consider these guidelines before beginning a study.
Significance level refers to the p-value threshold for concluding statistically significant results; it also corresponds to the type I error rate (the chance of concluding an effect when in fact none exists). In general, larger sample sizes are needed to detect a smaller effect size, achieve greater power, and/or reduce the type I error rate. In addition to these factors, sample size calculations for trials should anticipate loss to follow-up and withdrawals, patient non-compliance to treatment, and protocol violations and ineligibility.
Blinding
When the primary objective of a trial is to evaluate non-inferiority, an ITT analysis skews the data towards potentially showing non-inferiority. Because of this it is typical in non-inferiority trials to use an as-treated analysis as the primary analysis [39, 40]. The goal of this paper is to provide an initial guidance to investigators through the design process of a clinical trial.
Design and Interpretation of Clinical Trials
Different viral variants have also emerged during the pandemic, which may also influence outcomes, as have effective vaccines. For these reasons, concurrent controls are critical as a means to reduce temporal bias, though this feature is not common to all platform trials during the COVID-19 pandemic. In our view, this lesson should be an enduring one that lingers even after the pandemic has drawn to an end. Firstly, significance of the composite does not necessarily imply significance of the components nor does significance of the components necessarily imply significance of the composite. For example one intervention could be better on one component but worse on another and thus result in a non-significant composite.
Because of the increased probability of a false-positive conclusion discussed above all secondary objectives and analyses in a clinical trial should interpreted as non-definitive or hypothesis generating. When many “secondary” analyses are provided after the primary endpoint of a trial is not met, the results of any “significant” findings should be viewed with strong skepticism or outright ignored. Regression analyses are an important element of randomized trials analyses even when the primary analysis is not based on regression models.
There can be many logistic and ethical concerns in clinical trials where neither a placebo, nor a sham control can be applied. Blinding is especially important in studies where subjective response are considered as outcomes. This is because certain responses can be modified based on the knowledge of the experiment group that they are in. For example, a group allocated in the non‐intervention group may not feel better as they are not getting the treatment, or an investigator may pay more attention to the group receiving treatment, and thereby potentially affecting the final results.
The design should be led by this foundation, rather than the investigator retroactively trying to find data to support a faulty foundation. The greater the supporting data, the more complex and expensive the trial design can be, and vice-versa. It is critical to gather as much preliminary data as possible and to know how to interpret it in order to choose an appropriate trial design.
The scale of the primary endpoint impacts the analyses, trial power, and thus costs. Cohort studies can be classified as prospective and retrospective.7 Prospective cohort studies follow subjects from presence of risk factors/exposure to development of disease/outcome. This could take up to years before development of disease/outcome, and therefore is time consuming and expensive.
Active controls and placebo controls can be used simultaneously and provide useful data. For example, if the new intervention was unable to show superiority to placebo, but an active control group was able to demonstrate superiority to placebo, then this may be evidence that the new intervention is not effective. However, if the active control with established efficacy did not demonstrate superiority to placebo, then it is possible the trial was flawed or may have been underpowered because of the placebo response or variability being unexpected high. The selection of a control group is a critical decision in clinical trial design. The control group provides data about what would have happened to participants if they were not treated or had received a different intervention. Without a control group, researchers would be unable to discriminate the effects caused by the investigational intervention from effects due to the natural history of the disease, patient or clinician expectations, or the effects of other interventions.
The trial is working to automate data collection from electronic medical records in order to ease the burden of conducting time-sensitive research when resources may be overstretched. I-SPY COVID is also unique in its biomarker development initiative, which incorporates the collection and study of biospecimens to investigate the biologic heterogeneity of severe COVID-19 that may influence outcomes and/or treatment effects9. This is the ideal type of study to run, assuming there is enough preliminary data to effectively evaluate risks and benefits (and that the benefit/risk assessment is not based on wishful thinking or assumptions). Depending on the robustness of previous data, phase II, phase III or pivotal trials with clinically relevant outcomes can be run. For example, in Bolognini et al., 5 days of tDCS (a technique thought to be safe (48) that has been studied in neuropathic pain) led to a significant and sustained reduction of pain levels in PLP patients, along with an improved ability to move their limbs (10).
As chaotic as the early pandemic was, it also spurred tremendous innovation in clinical trial design. The RECOVERY adaptive platform trial in the United Kingdom demonstrated the substantial value of pragmatic phase 3 trials that could test a variety of well-established therapies in COVID-19, as has REMAP-CAP1,2,3,4,5. Despite the enormous contributions of these studies, there remained an unmet need for a phase 2 mechanism for rapidly screening and triaging potential treatments for severe COVID-19 in a systematic and expedient fashion. The selection of endpoints in a clinical trial is extremely important and requires a marriage of clinical relevance with statistical reasoning.
No comments:
Post a Comment